Plasma ultrafiltrable magnesium in insulin dependent diabetics

I R GUNN,* EILEEN BURNS†
From the Departments of *Chemical Pathology and †Medicine, St James’s University Hospital, Leeds

SUMMARY  Plasma ultrafiltrable (MgUF) and total magnesium concentrations were measured in 60 insulin dependent diabetics and compared with values in an age matched control group. Although the diabetic patients had lower plasma albumin concentrations (p < 0.05), both ultrafiltrable and total magnesium concentrations were significantly decreased by 6.8% and 7.6%, respectively, compared with those of the controls (p < 0.001). In the diabetic group MgUF varied inversely with fasting plasma glucose (r = −0.269, p < 0.05). In 14 patients with significant hypomagnesaemia, fasting plasma glucose concentration was higher (p < 0.01) and the diabetes was of shorter duration (p < 0.05) than in 46 patients with an MgUF in the control range. The fasting urinary magnesium creatinine ratio was greater in the diabetic patients (p < 0.05). Patients with retinopathy did not have lower plasma magnesium values than those without retinopathy.

There have been several reports of low plasma magnesium concentrations in patients with insulin dependent diabetes mellitus,1–8 and some suggest that the consequences may include increased risk of cardiovascular complications of the disease.2 4 5 9 Twenty five to 30% of plasma magnesium, however, is bound to proteins—mainly albumin. Binding of magnesium to albumin depends on the plasma pH. Plasma protein and pH disturbances are not unusual in diabetes, and it is conceivable that total magnesium concentrations which have been reported are not an accurate reflection of free plasma magnesium. In the absence of pH disturbances it may be possible to allow for plasma albumin variations by adjusting the measured total magnesium,10 but an alternative approach is direct measurement of the free plasma fraction. We measured plasma ultrafiltrable magnesium concentrations and, using two different analytical methods, total plasma magnesium concentrations in insulin dependent diabetics and control populations.

Material and methods

The control group consisted of 58 (23 men, 35 women) healthy laboratory staff and outpatients who had been referred for a glucose tolerance test, which was subsequently shown to be normal with no glycosuria. The patients comprised 60 (34 men, 26 women) type I diabetics who had volunteered to take part in the study as outpatients. Subjects taking diuretic treatment and those with a plasma creatinine concentration of more than 120 μmol/l were excluded. Permission for the study was granted by the local ethical committee.

Sampling procedures

All venous blood samples were taken with minimal venous stasis after the subject had fasted for 10 hours overnight. The subjects were seated for the sample but had been ambulant immediately before sampling.

Samples for ionised calcium and ultrafiltrable magnesium were maintained at in vivo pH by transferring the venous blood to fill completely a 12.5 ml lithium heparin tube and immediately proceeding to centrifuge, and then separating the plasma to perform the analysis.

Urine samples were obtained after a 10 hours overnight fast, the subject having discarded the first urine voided on rising.

Analytical methods

Ultrafiltrates of plasma were prepared by transferring 1.1 ml plasma to fill completely an Amicon Centrifree Micropartition device that was immediately spun at
Plasma ultrafilterable magnesium in insulin dependent diabetics

Table 1  Clinical and biochemical variables in controls and diabetic patients

<table>
<thead>
<tr>
<th></th>
<th>Controls (n = 58)</th>
<th>Patients (n = 60)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>Mean (SD)</td>
<td>Mean (SD)</td>
<td></td>
</tr>
<tr>
<td>39.3 (13.8)</td>
<td>34.6 (12.9)</td>
<td>NS</td>
<td></td>
</tr>
<tr>
<td>Duration of diabetes</td>
<td>13.2</td>
<td>7.9</td>
<td>NS</td>
</tr>
<tr>
<td>Mg$_{\text{Bu}}$</td>
<td>0.575* (0.040)</td>
<td>0.536 (0.045)</td>
<td>0.0002</td>
</tr>
<tr>
<td>Mg (atomic absorption)</td>
<td>0.800* (0.053)</td>
<td>0.739 (0.060)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Mg (calmagite)</td>
<td>0.889 (0.058)</td>
<td>0.825 (0.063)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Ca$^{2+}$ (7.4)</td>
<td>1.189 (0.031)</td>
<td>1.175 (0.034)</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td>Total calcium</td>
<td>2.366 (0.100)</td>
<td>2.345 (0.089)</td>
<td>NS</td>
</tr>
<tr>
<td>pH</td>
<td>7.383 (0.027)</td>
<td>7.381 (0.027)</td>
<td>NS</td>
</tr>
<tr>
<td>Albumin (g/l)</td>
<td>46.4 (2.7)</td>
<td>45.1 (3.4)</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td>Hba$_1$ (%)</td>
<td>6.83* (2.41)</td>
<td>10.42 (2.56)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Glucose</td>
<td>5.43 (1.02)</td>
<td>12.28 (6.11)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Creatinine (mmol/l)</td>
<td>83.3 (19.4)</td>
<td>79.1 (14.1)</td>
<td>NS</td>
</tr>
<tr>
<td>Cholesterol</td>
<td>6.16* (1.16)</td>
<td>6.03 (1.29)</td>
<td>NS</td>
</tr>
<tr>
<td>Triglyceride</td>
<td>0.75* (0.38)</td>
<td>0.83 (0.49)</td>
<td>NS</td>
</tr>
<tr>
<td>Urinary magnesium:creatinine ratio</td>
<td>0.229 (0.097)</td>
<td>0.285 (0.144)</td>
<td>&lt;0.05</td>
</tr>
</tbody>
</table>

* n = 27. Units are mmol/l, unless stated; p value calculated by unpaired t test.

2250 g for 15 minutes at a sample temperature of (26 SD 2)°C in a Wifug fixed angle centrifuge. Full details of the technique have been described elsewhere. Magnesium concentration in the ultrafiltrate was measured without delay using a Pye Unicam SP192 atomic absorption spectrophotometer. The in-trabatch coefficient of variation for the whole technique was 1.2% at Mg$_{\text{Bu}}$ values of 0.60 mmol/l.

Total magnesium concentrations were measured by atomic absorption (Pye Unicam SP192) and an automated method entailing complexing with Calmagite (American Monitor Parallel).

Iontised calcium concentrations and pH were measured on a Radiometer ICA-1 and adjusted to pH 7.4 by the formula built into that machine. Total plasma calcium was measured by cresolphthalein complexone; albumin by an automated short incubation time BCG method; creatinine by a kinetic Jaffe reaction; and cholesterol and triglycerides by automated enzymatic methods.

Glycosylated haemoglobin was measured by affinity electrophoresis, and glucose by a glucose oxidase method (Beckman).

Results

In the control group the only significant difference between men and women was in plasma creatinine concentration (mean 95.4 v 75.3 μmol/l), so that the predominance of men in the diabetic group was considered not to have biased the comparison. Table 1 shows that there was no significant difference in the ages between the two groups. The total plasma magnesium concentration was lower in the diabetic patients by both analytical methods, and despite a significantly lower albumin concentration and a tendency towards acidaemia, the mean Mg$_{\text{Bu}}$ concentration was correspondingly decreased by 6.8%. Fourteen (23%) of the diabetic patients also had Mg$_{\text{Bu}}$ values of more than 2 SD below the mean of the control group. The urine magnesium:creatinine ratio was higher in the diabetic group as a whole (p < 0.05), but the 14 patients with significant hypomagnesaemia had a lower ratio than the 46 others (p < 0.02).

No significant differences were observed between the mean of plasma creatinine, triglyceride, cholesterol and total calcium concentrations, but the ionised calcium value was slightly, but significantly, lower in the diabetic patients (p < 0.05).

Table 2 summarises some clinical and biochemical characteristics of the 14 diabetic patients with significant hypomagnesaemia. The most striking features were the higher fasting plasma glucose concentration and the shorter duration of the disease. There was also a tendency towards lower plasma calcium and albumin concentrations in this group. In the diabetic population as a whole Mg$_{\text{Bu}}$ correlated negatively with fasting plasma glucose concentration (r = 0.269), but not with Hba. Total magnesium did not have a significant correlation with plasma glucose, but it did correlate positively with plasma albumin concentration (r = 0.284, p < 0.05). The regression equation for total magnesium (measured by atomic absorption) on plasma albumin was:

\[ \text{Mg (mmol/l)} = 0.534 + (\text{albumin (g/l)} \times 0.0046) \]

Table 3 shows characteristics of patients with and without retinopathy. In those with mild eye signs the only difference of note was the longer duration of the
Table 3  Clinical and biochemical variables in patients with and without retinopathy

<table>
<thead>
<tr>
<th></th>
<th>No retinopathy</th>
<th>Retinopathy</th>
<th>Severe retinopathy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Duration (years)</td>
<td>10.9 (5.7)</td>
<td>20.3† (9.6)</td>
<td>27.4† (7.3)</td>
</tr>
<tr>
<td>Urea (mmol/l)</td>
<td>6.53 (1.33)</td>
<td>6.06 (1.92)</td>
<td>7.43* (2.48)</td>
</tr>
<tr>
<td>Creatinine (umol/l)</td>
<td>78.5 (12.0)</td>
<td>80.3 (18.0)</td>
<td>88.9 (22.4)</td>
</tr>
<tr>
<td>Albumin (g/l)</td>
<td>45.3 (3.1)</td>
<td>44.6 (3.9)</td>
<td>43.6* (2.6)</td>
</tr>
<tr>
<td>Total magnesium (mmol/l)</td>
<td>0.73 (0.063)</td>
<td>0.755 (0.051)</td>
<td>0.757 (0.057)</td>
</tr>
<tr>
<td>M_{EUF} (mmol/l)</td>
<td>0.533 (0.045)</td>
<td>0.542 (0.044)</td>
<td>0.550 (0.049)</td>
</tr>
<tr>
<td>HbA₁ (%)</td>
<td>10.1 (2.6)</td>
<td>11.1 (2.3)</td>
<td>13.5* (1.5)</td>
</tr>
</tbody>
</table>

*p < 0.01 compared with values in group with no retinopathy; †p < 0.001 compared with values in group with no retinopathy.

diabetes than in those with normal retinae. Patients with more severe haemorrhages and exudates and with new blood vessel formation had been diabetics for longer still, but in addition, had, on average, a higher plasma urea and HbA₁ concentration and lower plasma albumin value. There were no significant differences in plasma magnesium and lipid fractions between the three groups.

Discussion

We have shown for the first time that free plasma magnesium concentrations are low in diabetic patients treated with insulin. Twenty three per cent of patients had an M_{EUF} greater than 2 SD below the mean of the control population, compared with 25% found by Mather et al⁵ and 40% by McNair et al.¹² who measured total plasma magnesium concentration. In common with the findings of those studies, we found that low plasma magnesium concentrations were most commonly seen in patients with a high fasting plasma glucose value, but did not seem to be particularly related to metabolic control of the condition as assessed by glycosylated haemoglobin measurement. The 14 patients with significant hypomagnesaemia had a much higher average fasting glucose (16.1 ± 11.1 mmol/l), while there was negligible difference between the HbA₁ concentration of these 14 and the 46 patients with magnesium concentrations in the control range. In the whole group M_{EUF} varied inversely with fasting plasma glucose concentrations (p < 0.05), but not with HbA₁ values. Total magnesium did not correlate significantly with glucose.

Mather et al.¹³ showed that total plasma magnesium concentrations vary inversely with plasma glucose during daily fluctuations in individual diabetics, but their analysis was impeded by the complication of fluctuations in plasma albumin concentrations. Our demonstration of a strong correlation between M_{EUF} and glucose at a population level adds weight to the evidence that this is a true relation.

The mechanism of such a relation is not entirely clear. It may be that administration of exogenous insulin is responsible for the fall in magnesium, perhaps by uptake of magnesium into cells¹⁴ or increased urinary excretion of magnesium.¹² It has been shown, however, that total plasma magnesium concentrations after insulin administration tend to rise rather than fall in diabetic patients.¹³

One attractive possibility is that the hypomagnesaemia per se, perhaps through suboptimal performance of enzyme systems through which the action of insulin is mediated, renders control of diabetics more difficult. This has been shown in recovery from ketoacidosis.¹⁵ but it may apply to more stable diabetics. Such a mechanism would certainly account for the inverse relation between plasma magnesium and glucose concentrations and is also compatible with the association of increased urinary excretion of magnesium with an increased daily dose of insulin.¹²

There is evidence of tissue depletion of magnesium in insulin dependent diabetics. Erythrocyte magnesium has been shown to be depleted,⁵ as has bone content,¹⁶ although other work has reported no difference in erythrocyte, leucocyte, and muscle magnesium content.¹⁷ ¹⁸

The reason for the hypomagnesaemia in diabetic patients is almost certainly increased renal loss of magnesium, probably because hyperglycaemia inhibits tubular reabsorption of magnesium and calcium.¹⁹ Thus there may be a cycle in which glycosuria leads to hypomagnesaemia, which in turn leads to difficulty in controlling the diabetic condition, and thus increased likelihood of further glycosuria. This study confirms that increased urinary magnesium excretion occurs in diabetics, but we found the urinary magnesium:creatinine ratio to be lower in the 14 patients with hypomagnesaemia than in the other 46, and overall, a significant positive correlation between plasma magnesium and urine magnesium:creatinine ratio (p < 0.02). This is in contrast to the finding of McNair et al.¹²—increased urinary magnesium with lower plasma magnesium concentrations.

We concur with others² that significant hypomagnesaemia predominates in young diabetic patients with a shorter duration of the disease. This finding makes it difficult to explain the reports from other cross sectional studies that lower plasma mag-
Plasma ultrafiltrable magnesium in insulin dependent diabetics

Plasma ultrafiltrable magnesium values are present in diabetics with retinopathy. We did not find this to be the case. The only distinguishing feature of our patients with retinopathy was longer duration of disease, and in those with severe retinopathy, higher HbA1 and plasma urea values. A recently published longitudinal study has shown that duration of the disease is by far the most important influence on the development of retinopathy, with minor contributions from long term glycaemic control, serum triglycerides, and age. Unfortunately, the authors did not include measurement of plasma magnesium.

Plasma magnesium values tend to increase and albumin values to decrease with increasing age in control populations. Thus it is very difficult to draw logical conclusions from cross sectional studies measuring total plasma magnesium, when hypomagnesaemia seems to occur in patients with recent onset of diabetes, and retinopathy in those with disease of long duration.

A follow up study of the development of complications in young diabetic patients with hypomagnesaemia is mandatory to determine whether hypomagnesaemia is a risk factor for diabetic retinopathy or other complications. We have shown that despite significant hypoalbuminaemia in diabetic patients, there is a strong correlation between ultrafiltrable and total plasma magnesium, and there is a similar mean percentage decrease in the ultrafiltrable and total plasma magnesium concentrations compared with those of control groups. Therefore measurement of total plasma magnesium should be adequate in the planning of a longitudinal study.

References

11 Gunn IR. Measurement of plasma ultrafiltrable magnesium at in vivo pH. Submitted for publication.

Requests for reprints to: Dr IR Gunn, Department of Chemical Pathology, St James’s University Hospital, Leeds LS9 7TF, England.